Related Experiment Video

Updated: Jan 4, 2026

Establishing Cell Lines Overexpressing DR3 to Assess the Apoptotic Response to Anti-mitotic Therapeutics
12:28

Establishing Cell Lines Overexpressing DR3 to Assess the Apoptotic Response to Anti-mitotic Therapeutics

Published on: January 11, 2019

7.7K

Drugs and Clinical Approaches Targeting the Antiapoptotic Protein: A Review

Zeping Han1, Jiening Liang2, Yuguang Li1

  • 1Department of Laboratory Medicine, Central Hospital of Panyu District, Guangzhou, Guangdong 511400, China.

Biomed Research International
|October 31, 2019
PubMed

Insights

This review summarizes Bcl-2 inhibitors for cancer therapy, detailing mechanisms and clinical trial outcomes. It offers insights into developing novel biomedical approaches targeting Bcl-2 for future cancer treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • B-cell lymphoma 2 (Bcl-2) is a key regulator protein in apoptosis.
  • Dysregulation of Bcl-2 is implicated in various cancers.
  • Targeting Bcl-2 has shown promise in preclinical and clinical cancer therapy.

Purpose of the Study:

  • To review current Bcl-2 inhibitors and their mechanisms.
  • To analyze clinical trial results of Bcl-2 targeting agents.
  • To discuss the future potential of Bcl-2 inhibitors in cancer treatment.

Main Methods:

  • Literature review of Bcl-2 inhibitors.
  • Analysis of preclinical data and clinical trial outcomes.
  • Discussion of mechanisms of action and therapeutic efficacy.

Main Results:

  • Several Bcl-2 inhibitors (e.g., oblimersen, ABT-737, ABT-263) have been evaluated clinically.
  • Some agents demonstrated efficacy, while others did not meet expectations.
  • Understanding inhibitor mechanisms is crucial for therapeutic development.

Conclusions:

  • Bcl-2 inhibitors represent a significant area of cancer therapy research.
  • Further investigation into inhibitor mechanisms and clinical application is warranted.
  • Biomedical approaches targeting Bcl-2 hold potential for future cancer treatment strategies.

More Related Videos

Identifying Protein-protein Interaction Sites Using Peptide Arrays07:44

Identifying Protein-protein Interaction Sites Using Peptide Arrays

Published on: November 18, 2014

18.5K
Evaluation of Substrate Ubiquitylation by E3 Ubiquitin-ligase in Mammalian Cell Lysates09:47

Evaluation of Substrate Ubiquitylation by E3 Ubiquitin-ligase in Mammalian Cell Lysates

Published on: May 10, 2022

3.0K

Related Concept Videos

The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
8.1K
The Extrinsic Apoptotic Pathway01:17

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
7.9K
Apoptosis01:30

Apoptosis

Apoptosis is a combination of two Greek words, 'apo' and 'ptosis,' meaning separation and falling off, respectively. Hippocrates used this word to describe gangrene, which was caused due to bandaging of fractured bones. Apoptosis was distinguished from necrosis in 1970 when John Kerr reported observations of morphological changes occurring during apoptosis. During one experiment, he observed that the disruption of blood supply to the liver tissue resulted in a size...
13.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Autophagic Cell Death01:18

Autophagic Cell Death

Christian de Duve discovered “autophagy,” a process in which cellular components are engulfed by membrane-bound organelles called autophagosomes. The autophagosomes then fuse with lysosomes to digest the enclosed contents. Autophagy is generally activated in cells to prevent cell death. However, cell death is triggered when the damage is beyond repair.
Autophagy and Apoptosis
Autophagy can activate apoptosis. In normal conditions, the autophagy activating protein Beclin-1 and...
4.3K
Phagocytosis of Apoptotic Cells01:17

Phagocytosis of Apoptotic Cells

Cells undergoing apoptosis form apoptotic bodies that must be removed immediately to prevent inflammation, autoimmune diseases, and necrosis. Phagocytosis is carried out by professional phagocytes such as macrophages or  immature dendritic cells. Non-professional phagocytes such as  epithelial cells and fibroblasts also take part in this process; however, they are not as effective as professional phagocytes. 
Normal cells contain receptors that prevent them from being recognized...
4.8K